Does the media favor OPCH or CSTL?

In the previous week, Option Care Health and Option Care Health both had 3 articles in the media. Option Care Health's average media sentiment score of 1.34 beat Castle Biosciences' score of 1.30 indicating that Option Care Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Option Care Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CSTL or CRVL?

Castle Biosciences currently has a consensus price target of $42.00, indicating a potential upside of 41.80%. Given Castle Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Castle Biosciences is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Castle Biosciences 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 CorVel 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, CSTL or CRVL?

CorVel has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Castle Biosciences $344.23M 2.63 -$24.16M -$0.66 N/A CorVel $958.53M 3.50 $110.34M $2.25 29.21

Does the media prefer CSTL or CRVL?

In the previous week, Castle Biosciences and Castle Biosciences both had 3 articles in the media. CorVel's average media sentiment score of 1.37 beat Castle Biosciences' score of 1.30 indicating that CorVel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorVel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRVA or CSTL?

In the previous week, Privia Health Group had 7 more articles in the media than Castle Biosciences. MarketBeat recorded 10 mentions for Privia Health Group and 3 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 1.30 beat Privia Health Group's score of 0.67 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Privia Health Group 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PGNY or CSTL?

In the previous week, Progyny had 6 more articles in the media than Castle Biosciences. MarketBeat recorded 9 mentions for Progyny and 3 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 1.30 beat Progyny's score of 0.87 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ADUS or CSTL?

In the previous week, Addus HomeCare had 1 more articles in the media than Castle Biosciences. MarketBeat recorded 4 mentions for Addus HomeCare and 3 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 1.30 beat Addus HomeCare's score of 0.90 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addus HomeCare 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Castle Biosciences (CSTL) Competitors

$29.62 -0.93 (-3.04%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$29.61 -0.01 (-0.03%)

As of 08/14/2026 07:34 PM Eastern

Compare

CSTL vs. OPCH, CRVL, PRVA, PGNY, and ADUS

Should you buy Castle Biosciences stock or one of its competitors? Castle Biosciences's main competitors and comparable companies include Option Care Health (OPCH), CorVel (CRVL), Privia Health Group (PRVA), Progyny (PGNY), and Addus HomeCare (ADUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Castle Biosciences compare to Option Care Health?

Option Care Health (NASDAQ:OPCH) and Castle Biosciences (NASDAQ:CSTL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Option Care Health has a net margin of 3.68% compared to Castle Biosciences' net margin of -5.43%. Option Care Health's return on equity of 18.74% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Option Care Health	3.68%	18.74%	7.25%
Castle Biosciences	-5.43%	-4.15%	-3.45%

Option Care Health has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Option Care Health currently has a consensus target price of $29.92, indicating a potential upside of 24.99%. Castle Biosciences has a consensus target price of $42.00, indicating a potential upside of 41.80%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Castle Biosciences is more favorable than Option Care Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Option Care Health	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Option Care Health has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Option Care Health	$5.65B	0.63	$207.59M	$1.33	18.00
Castle Biosciences	$344.23M	2.63	-$24.16M	-$0.66	N/A

In the previous week, Option Care Health and Option Care Health both had 3 articles in the media. Option Care Health's average media sentiment score of 1.34 beat Castle Biosciences' score of 1.30 indicating that Option Care Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Option Care Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.1% of Option Care Health shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 1.7% of Option Care Health shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Option Care Health beats Castle Biosciences on 9 of the 15 factors compared between the two stocks.

How does Castle Biosciences compare to CorVel?

Castle Biosciences (NASDAQ:CSTL) and CorVel (NASDAQ:CRVL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Castle Biosciences currently has a consensus price target of $42.00, indicating a potential upside of 41.80%. Given Castle Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Castle Biosciences is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
CorVel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Castle Biosciences has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, CorVel has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

CorVel has a net margin of 11.72% compared to Castle Biosciences' net margin of -5.43%. CorVel's return on equity of 29.92% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-5.43%	-4.15%	-3.45%
CorVel	11.72%	29.92%	17.82%

CorVel has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	2.63	-$24.16M	-$0.66	N/A
CorVel	$958.53M	3.50	$110.34M	$2.25	29.21

92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 51.4% of CorVel shares are held by institutional investors. 6.1% of Castle Biosciences shares are held by company insiders. Comparatively, 39.7% of CorVel shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Castle Biosciences and Castle Biosciences both had 3 articles in the media. CorVel's average media sentiment score of 1.37 beat Castle Biosciences' score of 1.30 indicating that CorVel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorVel	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CorVel beats Castle Biosciences on 10 of the 15 factors compared between the two stocks.

How does Castle Biosciences compare to Privia Health Group?

Privia Health Group (NASDAQ:PRVA) and Castle Biosciences (NASDAQ:CSTL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

94.5% of Privia Health Group shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 5.7% of Privia Health Group shares are held by insiders. Comparatively, 6.1% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Privia Health Group has a net margin of 1.19% compared to Castle Biosciences' net margin of -5.43%. Privia Health Group's return on equity of 3.52% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Privia Health Group	1.19%	3.52%	2.00%
Castle Biosciences	-5.43%	-4.15%	-3.45%

Privia Health Group has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Privia Health Group	$2.12B	1.32	$22.92M	$0.21	104.76
Castle Biosciences	$344.23M	2.63	-$24.16M	-$0.66	N/A

In the previous week, Privia Health Group had 7 more articles in the media than Castle Biosciences. MarketBeat recorded 10 mentions for Privia Health Group and 3 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 1.30 beat Privia Health Group's score of 0.67 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Privia Health Group	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Privia Health Group has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Privia Health Group currently has a consensus target price of $31.00, suggesting a potential upside of 40.91%. Castle Biosciences has a consensus target price of $42.00, suggesting a potential upside of 41.80%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Castle Biosciences is more favorable than Privia Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Privia Health Group	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Privia Health Group beats Castle Biosciences on 10 of the 17 factors compared between the two stocks.

How does Castle Biosciences compare to Progyny?

Progyny (NASDAQ:PGNY) and Castle Biosciences (NASDAQ:CSTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Progyny has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.31B	1.54	$58.52M	$0.92	28.57
Castle Biosciences	$344.23M	2.63	-$24.16M	-$0.66	N/A

Progyny has a net margin of 6.00% compared to Castle Biosciences' net margin of -5.43%. Progyny's return on equity of 15.98% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Castle Biosciences	-5.43%	-4.15%	-3.45%

Progyny presently has a consensus price target of $34.10, suggesting a potential upside of 29.76%. Castle Biosciences has a consensus price target of $42.00, suggesting a potential upside of 41.80%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

94.9% of Progyny shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Progyny had 6 more articles in the media than Castle Biosciences. MarketBeat recorded 9 mentions for Progyny and 3 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 1.30 beat Progyny's score of 0.87 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Summary

Progyny beats Castle Biosciences on 13 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Addus HomeCare?

Addus HomeCare (NASDAQ:ADUS) and Castle Biosciences (NASDAQ:CSTL) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Addus HomeCare has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addus HomeCare	$1.42B	1.52	$95.91M	$5.70	20.36
Castle Biosciences	$344.23M	2.63	-$24.16M	-$0.66	N/A

In the previous week, Addus HomeCare had 1 more articles in the media than Castle Biosciences. MarketBeat recorded 4 mentions for Addus HomeCare and 3 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 1.30 beat Addus HomeCare's score of 0.90 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addus HomeCare	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Addus HomeCare has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Addus HomeCare presently has a consensus target price of $130.88, suggesting a potential upside of 12.76%. Castle Biosciences has a consensus target price of $42.00, suggesting a potential upside of 41.80%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Castle Biosciences is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

95.4% of Addus HomeCare shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 4.1% of Addus HomeCare shares are owned by insiders. Comparatively, 6.1% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Addus HomeCare has a net margin of 7.13% compared to Castle Biosciences' net margin of -5.43%. Addus HomeCare's return on equity of 9.96% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addus HomeCare	7.13%	9.96%	7.62%
Castle Biosciences	-5.43%	-4.15%	-3.45%

Summary

Addus HomeCare beats Castle Biosciences on 9 of the 15 factors compared between the two stocks.

Get Castle Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSTL vs. The Competition

Export

Metric	Castle Biosciences	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$933.29M	$9.80B	$7.05B	$13.10B
Dividend Yield	N/A	2.55%	2.57%	10.45%
P/E Ratio	-44.88	35.17	268.81	25.28
Price / Sales	2.63	4.74	585.96	81.62
Price / Cash	27.44	124.34	70.48	50.90
Price / Book	1.92	3.94	12.91	6.24
Net Income	-$24.16M	$309.96M	$3.45B	$347.60M
7 Day Performance	-7.52%	0.09%	1.11%	1.06%
1 Month Performance	23.31%	-0.33%	1.33%	0.81%
1 Year Performance	47.44%	19.52%	62.44%	20.90%

Castle Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSTL Castle Biosciences	3.5975 of 5 stars	$29.62 -3.0%	$42.00 +41.8%	+49.4%	$933.29M	$344.23M	N/A	540
OPCH Option Care Health	4.3406 of 5 stars	$23.55 -0.6%	$29.92 +27.1%	-15.7%	$3.53B	$5.65B	17.72	8,266	Positive News Analyst Upgrade
CRVL CorVel	1.4555 of 5 stars	$59.67 -1.6%	N/A	-25.7%	$3.04B	$958.53M	27.82	5,239	Positive News
PRVA Privia Health Group	4.5328 of 5 stars	$23.84 +0.2%	$31.15 +30.7%	+6.2%	$3.00B	$2.12B	149.00	1,226
PGNY Progyny	4.7729 of 5 stars	$31.54 +0.0%	$33.25 +5.4%	+16.5%	$2.47B	$1.29B	40.97	310	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSTL) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Castle Biosciences (CSTL) Competitors

CSTL vs. OPCH, CRVL, PRVA, PGNY, and ADUS

How does Castle Biosciences compare to Option Care Health?

Summary

How does Castle Biosciences compare to CorVel?

Summary

How does Castle Biosciences compare to Privia Health Group?

Summary

How does Castle Biosciences compare to Progyny?

Summary

How does Castle Biosciences compare to Addus HomeCare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Castle Biosciences (CSTL) Competitors

CSTL vs. OPCH, CRVL, PRVA, PGNY, and ADUS

How does Castle Biosciences compare to Option Care Health?

Is OPCH or CSTL more profitable?

Which has more volatility and risk, OPCH or CSTL?

Do analysts rate OPCH or CSTL?

Which has preferable earnings and valuation, OPCH or CSTL?

Does the media favor OPCH or CSTL?

Do institutionals & insiders hold more shares of OPCH or CSTL?

Summary

How does Castle Biosciences compare to CorVel?

Do analysts recommend CSTL or CRVL?

Which has more risk and volatility, CSTL or CRVL?

Is CSTL or CRVL more profitable?

Which has stronger earnings and valuation, CSTL or CRVL?

Do institutionals & insiders believe in CSTL or CRVL?

Does the media prefer CSTL or CRVL?

Summary

How does Castle Biosciences compare to Privia Health Group?

Do institutionals and insiders hold more shares of PRVA or CSTL?

Is PRVA or CSTL more profitable?

Which has preferable earnings & valuation, PRVA or CSTL?

Does the media favor PRVA or CSTL?

Which has more risk and volatility, PRVA or CSTL?

Do analysts rate PRVA or CSTL?

Summary

How does Castle Biosciences compare to Progyny?

Which has stronger valuation & earnings, PGNY or CSTL?

Is PGNY or CSTL more profitable?

Do analysts rate PGNY or CSTL?

Do institutionals & insiders hold more shares of PGNY or CSTL?

Does the media refer more to PGNY or CSTL?

Which has more risk & volatility, PGNY or CSTL?

Summary

How does Castle Biosciences compare to Addus HomeCare?

Which has stronger earnings & valuation, ADUS or CSTL?

Does the media favor ADUS or CSTL?

Which has more volatility and risk, ADUS or CSTL?

Do analysts recommend ADUS or CSTL?

Do insiders & institutionals hold more shares of ADUS or CSTL?

Is ADUS or CSTL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools